Home / Health / New Drugs Outperform Metformin for Prediabetes
New Drugs Outperform Metformin for Prediabetes
4 Nov
Summary
- GLP-1 drugs showed a 53% higher chance of normalizing blood sugar.
- Patients on GLP-1s had fewer heart attacks and strokes.
- These medications may be considered earlier for certain patients.
New research indicates that advanced weight-loss drugs, including Ozempic and Zepbound, offer superior outcomes for individuals with prediabetes compared to the standard medication metformin. A study presented at the American Heart Association meeting found that patients on GLP-1 drugs experienced a 53% greater likelihood of returning their blood sugar to normal levels.
These medications also demonstrated a 31% reduced risk of progressing to type 2 diabetes. Additionally, GLP-1 users saw a 15% decrease in heart attacks and a 20% reduction in strokes, alongside fewer instances of heart failure and atrial fibrillation.
Investigators suggest these findings may support earlier consideration of GLP-1 medications for specific patients. While metformin remains a safe and cost-effective first-line treatment, GLP-1s offer a promising alternative, particularly for those with prediabetes and obesity. Lifestyle changes remain a crucial component of treatment.
The benefits are largely attributed to the significant weight loss induced by GLP-1 drugs. Preventing the transition from prediabetes to type 2 diabetes is key to avoiding serious cardiovascular events. Access and cost are important factors in considering these medications.
